BridgeBio Pharma to Participate in the 45th Annual Goldman Sachs Global Healthcare Conference
06 June 2024 - 9:30PM
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the
“Company”), a commercial-stage biopharmaceutical company focused on
genetic diseases and cancers, today announced that Neil Kumar,
Ph.D., founder and CEO of BridgeBio, will present at the
Goldman Sachs Annual Global Healthcare Conference in Miami, FL on
Wednesday, June 12 at 3:20 pm EDT.
To access the live webcast of BridgeBio’s presentation, please
visit the “Events & Presentations” page within the Investors
section of the BridgeBio website
at http://investor.bridgebio.com. A replay of
the webcast will be available on the BridgeBio website for 90 days
following the event.
About BridgeBio Pharma, Inc. BridgeBio
Pharma, Inc. (BridgeBio) is a commercial-stage biopharmaceutical
company founded to discover, create, test, and deliver
transformative medicines to treat patients who suffer from genetic
diseases and cancers with clear genetic drivers. BridgeBio’s
pipeline of development programs ranges from early science to
advanced clinical trials. BridgeBio was founded in 2015 and its
team of experienced drug discoverers, developers, and innovators
are committed to applying advances in genetic medicine to help
patients as quickly as possible. For more information
visit bridgebio.com and follow us
on LinkedIn and Twitter.
BridgeBio Contact: Vikram
Bali contact@bridgebio.com (650)-789-8220
BridgeBio Pharma (NASDAQ:BBIO)
Historical Stock Chart
From May 2024 to Jun 2024
BridgeBio Pharma (NASDAQ:BBIO)
Historical Stock Chart
From Jun 2023 to Jun 2024